Pfizer 2011 Annual Review | Pfizer: the world's largest research-based pharmaceutical company

Biopharmaceutical Businesses

Our patient-centric, customer-facing biopharmaceuticals businesses are responsible for life cycle management of promising new medicines that have achieved "proof of concept" in our labs. They also ensure that patient and customer needs inform the development of new medicines and vaccines.


    Our Primary Care unit offers solutions that help patients and health care providers manage chronic, costly conditions, and improve outcomes and overall health. Through leadership in areas such as the management of pain, heart disease and depression, Primary Care medicines treat conditions that account for a large and growing portion of the world's health care costs. Our pipeline includes molecules with potential in women's health, pain, cardiovascular and metabolic diseases, allergy and respiratory, and Alzheimer's disease and other dementias.

    2011 Highlights

    • Eliquis (apixaban) approved in Europe for the prevention of venous thromboembolism (blood clots) in joint replacement patients; accepted for review in Europe and the U.S. for stroke prevention in patients with atrial fibrillation.

    • Oxecta (oxycodone HCL, USP), Tablets CII approved in the U.S. for management of acute and chronic pain and utilizing technologies designed to deter abuse and misuse.

    • Pediatric study led to approval in Europe of a chewable form of Lipitor (atorvastatin) to treat children with hypercholesterolemia (the presence of high cholesterol in the blood) and six-month extension of Lipitor exclusivity in many parts of the European Union. Hypercholesterolemia increases children's risk of developing cardiovascular disease later in life.

    • Completed acquisition of King Pharmaceuticals, supplementing Pfizer's long-standing strength in pain management.

    • Completed acquisition of Icagen, Inc., an innovative leader in pain research, adding extensive research expertise and technology in the field of ion channels and enhancing Pfizer's ability to develop potential first-in-industry drugs for the treatment of pain and related conditions.

    For more information visit Pfizer Pharmaceutical Products.


    Our Specialty Care unit features a robust portfolio of market-leading medicines and is a leader in vaccines and the treatment of inflammation, two important areas of innovation and growth in biomedical science. In addition, Specialty Care understands the devastating impact of rare diseases on patients and is dedicated to addressing these serious unmet medical needs by seeking to discover, develop and deliver treatments for them. Specialty Care medicines help address potentially life-threatening and debilitating diseases at every stage of life.

    2011 Highlights

    Prevnar 13/Prevenar 13

    • Approved for various indications in adults 50 years and older in the U.S., EU, Australia and more than 10 other countries.
    • Approved for infants and young children in more than 110 countries, launched in nearly all places where approved, and part of more than 55 national childhood immunization programs—reflecting 100 percent growth versus 2010.
    • Introduced in the national childhood immunization programs of 14 of 16 developing countries that have launched programs under the auspices of the Advance Market Commitment. The AMC is an innovative private-public health program designed to accelerate access to pneumococcal vaccination in poor countries on an affordable and sustainable basis.
    • Recognized with the 2011 Prix Galien USA Award for "Best Pharmaceutical Agent"—considered among the industry's highest accolades for excellence in scientific innovation that improves the state of human health.

    • Reported results of Phase III pivotal trials for this novel, oral JAK inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for moderate-to-severe active rheumatoid arthritis.
    • Applications for marketing approval of tofacitinib for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis have been filed with regulatory authorities in the U.S., Europe, Japan and Switzerland.
    • Pfizer is also studying oral tofacitinib in psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, inflammatory bowel disease (ulcerative colitis and Crohn's disease) and renal transplant, and topical tofacitinib in both psoriasis and dry-eye disease.
    Enbrel (etanercept)

    • In the U.S., along with our marketing partner Amgen, launched an integrated print, digital, TV and disease awareness campaign featuring world-class golfer and psoriatic arthritis patient Phil Mickelson. This successful campaign empowers patients with psoriatic arthritis, rheumatoid arthritis or plaque psoriasis to take action and educate themselves about their condition and work with a medical specialist to make an informed decision about treatment options.
    Vyndaqel (tafamidis)

    • Vyndaqel is the first therapy approved in the European Union for the rare and fatal neurodegenerative disease transthyretin familial amyloid polyneuropathy (TTR-FAP). It is indicated in the EU for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy, to delay peripheral neurologic impairment.

    For more information visit Pfizer Pharmaceutical Products.


    Oncology investigates the complexities of cancer to discover and develop innovative treatment options and bring them to patients worldwide. Our robust oncology pipeline has both biologics and small-molecule compounds in development, including several first-in-class treatment candidates, with more than 100 clinical trials under way.

    2011 Highlights

    • Unprecedented number of regulatory filings: Xalkori (crizotinib) in the U.S., EU and Japan; Inlyta (axitinib) in the EU, Japan, and U.S.; and bosutinib in the U.S. and EU.

    • Xalkori (crizotinib) approved in the U.S. and Korea as first and only therapy for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer. Within one business day of approval, Xalkori was available nationwide in the U.S.

    • Crizotinib discovery chemistry team, led by Dr. J. Jean Cui, recognized as "Inventors of the Year" by the Intellectual Property Owners Association.

    • Sutent (sunitinib malate) approved in the U.S. for a third indication—the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease, a rare cancer reported in two to four people per million annually worldwide.

    • Maintained and expanded advanced renal cell carcinoma franchise, which includes Sutent, Torisel (temsirolimus) and Inlyta (axitinib), which is approved in the U.S. and under review by regulatory agencies in EU and Japan.

    • Showcased growing hematology franchise, with key data on bosutinib presented at 2011 oncology congresses.

    • Focused and refined pipeline, advancing key compounds into Phase III trials, including the investigational agents dacomitinib and inotuzumab, and established innovative partnerships and collaborative relationships for the continued clinical development of promising compounds both within and outside of Pfizer.

    For more information visit Pfizer Pharmaceutical Products.


    Emerging Markets and Established Products offer large growth opportunities for Pfizer to reach more patients around the world with its high quality medicines. The global off-patent pharmaceutical field is one of the fastest-growing segments in the global pharmaceutical marketplace.

    Today, 79 percent of prescriptions in the U.S. are filled with generics and other off-patent medicines. By 2020, off-patent medicines and their generic equivalents are estimated to account for more than 50 percent of global pharmaceutical sales. Currently, we have over 600 off-patent Pfizer legacy brands and other generic products in our Established Products portfolio that we offer at the highest quality standards with consistency of supply.

    As one of the leading pharmaceutical companies in emerging markets, Pfizer brings its innovation and high quality medicines to over 70 emerging countries. We do so by offering our Primary Care, Specialty, Oncology and Vaccines portfolios.

    2011 Highlights

    • In Emerging Markets, we offer Prevenar 13 Pediatric to help protect millions of children from pneumococcal disease in over 97 emerging markets around the world, including 14 underdeveloped markets via the GAVI-AMC initiative. Pfizer also gained approval for Prevenar 13 Adult indication in 20 emerging markets, giving us the opportunity to help protect Adults 50+ from pneumococcal disease.

    • Pfizer introduced the "Lipitor For You" program, which makes it possible for many patients to remain on Lipitor, a brand they know and trust in the face of generic competition.

    • Throughout 2011, we were able to supply patients, particularly those in the U.S., with medications that faced sudden and critical supply shortages. This was accomplished by leveraging Pfizer's global scale and rapidly responding to competitors' supply interruptions.